Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

J&J/Bayer’s Rivaroxaban Clinical Program Reports Few Liver Toxicity Cases

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Oral Factor Xa inhibitor will be filed mid-year for prevention of venous thromboembolism in orthopedic surgery patients.

You may also be interested in...



Safety Results Prompt Bristol To Refine Apixaban Dosing In Acute Coronary Syndrome Trials

Firm is discussing Phase III design with regulators.

Safety Results Prompt Bristol To Refine Apixaban Dosing In Acute Coronary Syndrome Trials

Firm is discussing Phase III design with regulators.

With European Approval Imminent, J&J/Bayer File Rivaroxaban In The U.S.

Novel anticoagulant for orthopedic surgery poised to reach market before Pfizer, Bristol, Astellas and Daiichi Sankyo compounds.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS067842

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By